Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10487140

    Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10485841

    Method for producing dry extracts

    BIONORICA SE · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10487076

    Compositions and methods for treating diseases and conditions

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10487088

    Tricyclic compound serving as immunomodulator

    Medshine Discovery Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10485879

    Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues

    Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10485850

    Methods for producing stable therapeutic formulations in aprotic polar solvents

    XERIS PHARMACEUTICALS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10485829

    Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

    Astellas Institute for Regenerative Medicine · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10485792

    Sustained release delivery systems for the prevention and treatment of head and neck cancers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10485774

    Enterically coated cysteamine, cystamine and derivatives thereof

    The Regents of the University of California · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10485959

    Drug releasing coatings for balloon catheters

    Lutonix, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10487054

    Therapeutic compounds

    Regents of the University of Minnesota · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10488417

    Compounds for use as imaging agents

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10487341

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10488416

    Targeting breast cancer therapy based on stromal subtypes and CD146 composition

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10487326

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10487148

    Methods and compositions for treating aging-associated impairments

    The Regents of the University of California · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10487113

    Peptide having activity to improve skin condition and use thereof

    CAREGEN CO., LTD. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10487145

    Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10487105

    Trinucleotide MRNA cap analogs

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10485869

    Etanercept formulations stabilized with meglumine

    Coherus BioSciences, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10485871

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10485844

    Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10485877

    Oligomer-phenothiazine conjugates

    Nektar Therapeutics · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10485958

    Drug releasing coatings for balloon catheters

    Lutonix, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10485886

    Core-satellite nanocomposites for MRI and photothermal therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. WO 2019224246

    MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE

    ALK ABELLO AS [DK] · Granted Thu Nov 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10494401

    LLP2A-bisphosphonate conjugates for osteoporosis treatment

    The Regents of the University of California · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10494405

    Methods and compositions for the treatment of arthritis

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10494619

    High isomerohydrolase activity mutants of human RPE65

    The Board of Regents of the University of Oklahoma · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10494440

    Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

    VACCINEX, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10494648

    Delivery methods and compositions for nuclease-mediated genome engineering

    Sangamo Therapeutics, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10493253

    Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10494632

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10494444

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10495650

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10494612

    Adeno-associated virus virions with variant capsid and methods of use thereof

    The Regents of the University of California · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10494442

    Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10494435

    Human monoclonal antibodies specific for CD22

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10494364

    Cathepsin K inhibitors and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10494327

    Controlled release pharmaceutical formulations

    United Therapeutics Corporation · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10493081

    Methods for treatment of diseases

    Galera Labs, LLC · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10493077

    Fused imidazo-piperidine JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10493038

    Formulation of acoustically activatable particles having low vaporization energy and methods for using same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10492477

    Humanized C5 animals

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10492518

    Blood lipid-lowering composition, method for preparing the same and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10493087

    Sialylation-increasing therapies for diseases associated with oxidative stress

    The United States of America, as represented by National Institute of Health · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10493030

    Combination HIV therapeutic

    Aphios Corporation · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10493037

    Multiphasic particles fabricated by wettability engendered templated self-assembly (WETS) methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.